Abstract
This review deals with the blood-brain-barrier (BBB) as it relates to multiple sclerosis (MS). The MS BBB is discussed in relation to the following: postmortem perfusion utilizing trypan blue; circulating serum albumin as a marker of the normalcy of tight junctions of the endothelium of the CNS; CSF albumin as a marker of the BBB in MS; in vivo detection of an altered BBB of MS lesions utilizing computer tomography of the brain; detection of de novo central nervous system (CNS) IgG synthesis with or without an altered BBB; utilization of a formula to estimate de novo CNS IgG synthesis to evaluate putative therapies. In addition, a proposal is made that there exist within the BBB in MS two interlaced colonies of immunocytes capable of synthesizing IgG in concert or independently. Colony 1 consists of B lymphocytes that may be preprogrammed to antigens experienced by the core immune network, and that are recruited from the blood to the CNS by chemotaxis. This type of immunologic appearance could replicate the MS patient's antigenic exposure and reward the CNS in MS with focal, in situ synthesized antibodies, hence imparting to the CNS an expeditious super-resistance. Colony 2 consists of resident plasma cells attributable to a persistent in situ antigenic stimulation, presumably owing to the MS antigen. Finally, since the CNS in MS has been provoked to become a type of immune organ-that is, it is able to synthesize IgG de novo—it is reasonable to propose the following: That de novo IgG in the CNSKSF, especially oligoclonal IgG, is antibody in excess of its antigen. We believe it can be used as an antibody reagent to search for the persistent antigenic stimulus present most appropriately at the periplaque edge, which might presumably turn out to be related to the cause of MS.
- © 1978 by the American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
